Novartis AG (NYSE:NVS) saw unusually-strong trading volume on Thursday . Approximately 1,075,652 shares traded hands during trading, a decline of 3% from the previous session’s volume of 1,104,592 shares.The stock last traded at $80.04 and had previously closed at $80.30.

A number of research analysts recently issued reports on NVS shares. Jefferies Group restated a “buy” rating on shares of Novartis AG in a report on Friday, May 13th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis AG in a research report on Thursday, May 19th. Zacks Investment Research raised Novartis AG from a “hold” rating to a “buy” rating and set a $92.00 price objective on the stock in a research report on Monday, July 11th. TheStreet raised Novartis AG from a “hold” rating to a “buy” rating in a research report on Friday, June 24th. Finally, Bank of America Corp. reaffirmed a “hold” rating on shares of Novartis AG in a research report on Wednesday, May 18th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and an average target price of $91.20.

The stock has a market capitalization of $188.85 billion and a P/E ratio of 28.31. The firm has a 50-day moving average price of $82.14 and a 200 day moving average price of $77.48.

Novartis AG (NYSE:NVS) last issued its earnings results on Tuesday, July 19th. The company reported $1.23 EPS for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.05. The company had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. During the same period last year, the business posted $1.25 earnings per share. Equities research analysts anticipate that Novartis AG will post $4.73 earnings per share for the current year.

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.